Psilocybin Mushrooms

What Psilocybin Is

Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is a naturally occurring tryptamine alkaloid found in more than 200 species of fungi distributed across every major continent. After ingestion it is rapidly dephosphorylated in the body to psilocin, the pharmacologically active compound, which binds primarily at serotonin 5-HT2A receptors in the brain and produces the characteristic psychedelic experience.

The genus Psilocybe contains the largest number of psilocybin-producing species, with Psilocybe cubensis being the most widely cultivated and therefore most commonly encountered in the contemporary West. Other significant species include P. semilanceata (liberty cap), P. azurescens, and P. cyanescens, which can contain substantially higher psilocybin concentrations than P. cubensis. Potency varies considerably not just between species but between individual specimens, flushes, and growing conditions, a practical consideration for anyone planning an experience.

Psilocybin is a secondary metabolite, a biochemical compound not essential to basic cellular function but produced at metabolic cost, and it has significant effects on the organisms that encounter it. Analyses of fungal biosynthetic gene clusters indicate that psilocybin evolved independently at least twice in distantly related lineages, a rare instance of convergent evolution in natural product biosynthesis. Horizontal transfer of the gene cluster between fungi sharing the same habitats appears to have spread it further (Meyer & Slot, 2023; Reynolds et al., 2018).

What makes this more than a genomic curiosity is where it happened. The fungi carrying the cluster largely live in dung and decaying wood, which are insect-rich environments. That suggests psilocybin conferred an ecological advantage there, most likely in interactions with insects or other decomposers rather than in any relation to humans. The compound was doing ecological work in soil and rotting matter long before it met a human nervous system. That we respond to it so profoundly reflects our embeddedness in a deeply conserved serotonergic neurochemistry shared across species. Not design, and not intent.

Species Guide

All Psilocybe species produce psilocybin and psilocin, but vary considerably in potency, habitat, and availability. The four species most likely to be encountered in the contemporary West are:

Potency estimates above are approximate and based on average measured psilocybin/psilocin content; individual specimens can vary considerably. P. cubensis cultivars have been selectively developed for consistency and yield, "cube" varieties (Golden Teacher, B+, Penis Envy, and others) vary in average potency, with Penis Envy and its derivatives consistently producing higher psilocybin concentrations than standard cubensis strains. Penis Envy is typically estimated at 1.5 to 2 times the potency of average cubensis, placing it closer to the moderate-high range.

Any dose calibrated to dried P. cubensis needs significant adjustment if using another species or a high-potency cultivar. Starting with a substantially lower gram weight and waiting the full onset window before reassessing is essential when working with unfamiliar material.

History & Cultural Roots

Psilocybin mushrooms have been used ceremonially by Indigenous peoples of Mesoamerica for millennia. Mushroom stones dating to roughly 1000 BCE have been recovered in highland Guatemala, and archaeological and ethnobotanical evidence indicates continuous use through to the present day. In Mazatec communities in Oaxaca, Mexico, psilocybin mushrooms (known as ndi xi tho, or "that which springs forth") are understood as persons or teachers whose healing knowledge is accessed through reciprocal ceremonial engagement rather than extracted as a pharmaceutical resource (Estrada, 1981). These ceremonies, led by curandera/os, are embedded within particular landscapes, cosmological frameworks, and social obligations. The mushrooms are not consumed; they are met.

The encounter that introduced psilocybin mushrooms to Western popular culture took place in 1955, when American banker and ethnomycologist R. Gordon Wasson participated in a Mazatec velada led by María Sabina, and then published an account of it in Life magazine in 1957. What followed is taken up under ethics and sovereignty.

From Wasson's publication, psilocybin reached Timothy Leary and colleagues at Harvard, triggering the Psilocybin Project (1960–62) and the broader 1960s psychedelic movement. Following the passage of the Controlled Substances Act in the United States in 1970, which placed psilocybin in Schedule I alongside heroin, research was effectively halted for several decades. The modern resurgence began in the mid-1990s with a small number of researchers, most notably at Johns Hopkins and New York University, who succeeded in obtaining regulatory approval for controlled clinical studies. Since roughly 2010, the volume of clinical and scientific research has grown substantially, and psilocybin now sits at the centre of what many researchers describe as a genuine therapeutic renaissance.

Ethics and Sovereignty

The consequences of Wasson's 1957 article were swift and largely damaging. Oaxaca filled with Westerners looking for mushrooms. María Sabina was ostracised by her own community for having shared ceremonial knowledge with outsiders, her house was burned, and she died in poverty. The mushrooms became objects of tourism in a context bearing little resemblance to the tradition they came from. She later said that from the moment the foreigners arrived, the mushrooms lost their purity and their force.

That episode is the template for nearly everything that has happened since between Western interest and Indigenous psychedelic practice, which is why it belongs on this page rather than filed away as background. The pattern is consistent: an outsider is admitted to a tradition on terms of trust, publishes, and the resulting attention is borne almost entirely by the community rather than by the person who wrote it down.

Psilocybin's position today differs from ayahuasca's or mescaline's in one practical respect that matters. P. cubensis is cultivated at home worldwide, the supply depends on no wild population and no Indigenous territory, and almost no one taking psilocybin in the West is drawing on Mazatec resources. The ecological and extractive pressures that make peyote sourcing a live ethical question simply do not apply here.

What remains is a question about framing rather than supply. Mazatec practice treats the mushrooms as persons to be met, within a ceremony held for a purpose, by someone accountable to a community. Western practice generally does not, and there is no obligation on anyone to adopt a cosmology they do not hold. The honest position is to be clear about which you are doing: someone growing mushrooms at home and taking them thoughtfully is doing a genuine thing, and calling it a velada or borrowing the language of a tradition they have no relationship with adds nothing but a claim they cannot support.

Where it does become a live question is in paid ceremony. Retreats that market Mazatec or broadly Indigenous framing to outsiders, without accountability to or benefit for those communities, are reproducing the 1957 dynamic with a price list attached. The questions worth asking are the same as anywhere: who is this person accountable to, and does anything return to the tradition being invoked.

How Psilocybin Works

Pharmacology: the prodrug mechanism

Psilocybin is technically a prodrug. After ingestion, it is dephosphorylated by alkaline phosphatase enzymes in the small intestine and liver, converting rapidly to psilocin (4-hydroxy-DMT), the compound actually responsible for psychedelic effects. Psilocin's molecular structure closely resembles serotonin (5-hydroxytryptamine), allowing it to bind with high affinity at serotonin receptor subtypes throughout the brain and body. Its primary psychedelic effects are mediated by partial agonism at 5-HT2A receptors, which are densely expressed in the cortex, particularly in the prefrontal and parietal regions involved in perception, attention, and self-referential processing.

This 5-HT2A agonism triggers a cascade of downstream effects: increased glutamate release in the prefrontal cortex, altered thalamocortical gating (which normally filters sensory signals), and changes in how different brain regions communicate with one another. Psilocin is also a partial agonist at 5-HT2C and 5-HT1A receptors, contributing to the anxiolytic and mood-elevating qualities some people experience.

The REBUS model: loosening predictive priors

The most influential current framework for understanding psychedelics at the network level is the REBUS model (Relaxed Beliefs Under Psychedelics), proposed by Carhart-Harris and Friston (2019) and grounded in Karl Friston's predictive processing account of brain function. In this view, the brain does not passively receive sensory information, it continuously generates predictions about what it expects to perceive, and filters incoming signals through those top-down predictive models. Most of what we experience as perception is the brain's best guess, updated only when prediction errors become large enough to force revision.

Psilocybin attenuates the precision weighting assigned to these top-down priors, effectively loosening the grip of habitual predictive models on perception and cognition. The result is increased influence of bottom-up sensory signals: richer, less filtered incoming information from the body and environment. The system becomes temporarily less hierarchically organised, more open to what is actually arriving through the senses. This accounts for both the perceptual richness of psychedelic experience (heightened colour, texture, sound, movement) and for cognitive phenomena like novel associations, loosening of habitual thought patterns, and the increased salience of previously backgrounded sensory features, including ecological ones.

The default mode network and ego dissolution

Neuroimaging studies consistently show that psilocybin reduces activity and functional coherence in the default mode network (DMN), a set of midline cortical regions active during self-referential thought, autobiographical memory, mind-wandering, and the ongoing narrative construction through which we maintain a sense of who we are. The DMN is closely associated with what is sometimes called the narrative self: the continuous internal story that presents as "I, here, doing this."

Psilocybin's disruption of DMN activity corresponds experientially to the loosening of self-world boundaries, and at higher doses, ego dissolution, a temporary collapse of the ordinary sense of being a bounded self separate from the world. This is one of the most replicated findings in psychedelic neuroimaging, and the degree of DMN disruption correlates with the intensity of subjective self-transcendence. DMN disruption also mediates a significant portion of the relationship between psilocybin and therapeutic outcomes, suggesting that the temporary suspension of the narrative self is functionally important for cognitive and emotional reorganisation.

These accounts describe mechanism. They explain less well why psychedelic experiences take the particular phenomenological forms they do, why boundary dissolution so often becomes ecological boundary dissolution. That question needs a broader framework than neuroimaging provides; our Science page takes it up under enactive cognition.

Effects

Psilocybin experiences are shaped profoundly by dose, individual psychology, cultural context, and physical environment, what researchers and practitioners call set and setting. The following describes moderate-to-high dose experiences in typical conditions. Lower doses produce milder, more manageable versions of these effects; very high doses can produce experiences that are substantially more intense and less characterisable.

Onset (20–60 minutes)

The onset phase is frequently accompanied by physical sensations (warmth, tingling, yawning, and mild nausea in some people) alongside early emotional sensitivity and the first perceptual shifts. Colours may appear more vivid, geometric patterns may begin appearing in peripheral vision, and there is often a recognisable quality of heightened attentiveness to sounds, textures, and light. Mild anxiety as effects build is common and generally transient; having trusted company or a prepared environment helps considerably during this window.

Peak (2–4 hours)

At moderate doses, the peak involves significant perceptual shifts including visual distortions, enhanced colour saturation, and altered time perception, minutes can feel like hours. Emotional amplification is characteristic: whatever emotional material is present tends to become more vivid and more available for examination. Habitual patterns of self-referential thought relax.

At higher doses, these effects intensify substantially. The habitual boundary between self and world (the sense of being a separate, enclosed subject encountering an external world of distinct objects) softens or dissolves. Participants describe merging with their surroundings, feeling that "the boundary between myself and the world dissolved," or experiencing themselves as "part of everything." At the higher end of dose ranges, complete ego dissolution becomes possible: a temporary loss of the ordinary sense of being a person at all, leaving only awareness without a centre.

Three phenomenological features appear consistently in qualitative and clinical research and are associated with therapeutic benefit: boundary dissolution and self-transcendence; heightened perception of aliveness and animacy in the more-than-human world (trees, fungi, water, and other organisms encountered as lively, responsive, and communicative rather than inert); and affectively charged insights into interconnection and ecological embeddedness, the felt realisation that one's life is part of a larger living system.

Descent and afterglow (3–6+ hours)

The return to baseline is typically gradual, with a reflective quality. Full baseline is usually reached within six hours of ingestion, significantly shorter than LSD (8–12 hours), which is one reason psilocybin has become preferred in therapeutic research. A residual sense of openness, emotional accessibility, and perceptual freshness frequently persists into the following day, sometimes called the afterglow, and this window is particularly valuable for integration work.

Dosage Reference

Ranges below reflect commonly reported thresholds for dried Psilocybe cubensis. Potency varies significantly between specimens. Individual response varies with body chemistry, history, and set and setting. This is reference information, not a recommendation to use any particular dose.

Note that these gram weights apply to P. cubensis specifically. More potent species such as P. azurescens may produce equivalent or greater effects at 30–50% of these amounts. Lemon tekking, soaking mushrooms in acidic lemon juice prior to consumption, is reported to accelerate onset and intensity by pre-converting psilocybin to psilocin outside the body.

Methods of consumption

How mushrooms are prepared and consumed affects onset timing, intensity, and nausea. The following are the most common approaches:

Dried mushrooms, whole. The simplest and most common method. Dried mushrooms are chewed thoroughly and swallowed. Onset typically begins 30–60 minutes after ingestion, depending on stomach contents. Nausea during onset is relatively common, chitin in the mushroom cell walls is difficult to digest, and some people find it worthwhile to grind mushrooms to a fine powder before consuming to reduce this.

Mushroom tea. Ground or chopped dried mushrooms are steeped in hot (not boiling) water (typically 70–80°C) for 15–20 minutes, then strained. The resulting liquid is consumed; some people consume the spent mushroom material as well, others discard it. Tea typically produces a faster, cleaner onset (20–40 minutes) with reduced nausea compared to eating whole mushrooms. Adding lemon, ginger, or honey is common; lemon also functions as a mild acid that begins converting psilocybin to psilocin before consumption, sharpening onset.

Lemon tek. Lemon tek is the most widely discussed preparation method. Finely ground dried mushrooms are submerged in freshly squeezed lemon (or lime) juice for 15–20 minutes, stirring occasionally, then consumed directly, juice and all. The acidity mimics the stomach's conversion of psilocybin to psilocin, effectively pre-converting a significant proportion before ingestion. Reported effects include faster onset (15–30 minutes), greater peak intensity, and sometimes shorter overall duration. Many people find it reduces nausea. The increased speed and intensity of lemon tek means dose reduction of 20–30% is advisable for those new to this method.

Capsules. Ground mushroom powder is encapsulated. This approach offers precise dosing and avoids the taste and texture of whole mushrooms. Onset is typically similar to whole dried mushrooms. Capsules are widely used for microdosing protocols because they allow consistent sub-perceptual dosing without variation.

Chocolate and edibles. Powdered mushrooms embedded in chocolate or other food. This is largely aesthetic, the food matrix does not significantly change the pharmacological properties, though fats may slightly delay or smooth onset in some cases. Accurate dosing can be more difficult with homemade preparations unless careful weight measurements are used in production.

What the Research Shows

Psilocybin is now among the most extensively studied classic psychedelics in controlled clinical research. The findings across several indication areas are striking enough to have prompted the FDA to grant it Breakthrough Therapy designation, a status intended to accelerate the development of treatments for serious conditions where preliminary evidence suggests substantial improvement over available treatments. Below is an honest summary of where the evidence stands.

Depression

Multiple randomised controlled trials have found significant antidepressant effects. Davis and colleagues (2021, JAMA Psychiatry) found large effect sizes for major depressive disorder in a controlled trial, with effects persisting at 4-week follow-up. A landmark trial at Imperial College London compared psilocybin therapy to the SSRI escitalopram over six weeks and found comparable, and on several measures superior, antidepressant effects, with psilocybin associated with greater increases in emotional responsiveness and connectedness (Carhart-Harris et al., 2021). Compass Pathways' Phase 2b trial of COMP360 (synthetic psilocybin) across 233 participants with treatment-resistant depression found significant reductions in depression scores at the highest dose, though the effect at lower doses was not significant, underscoring that dose matters and that results are not uniform across individuals or populations.

End-of-life distress and existential anxiety

Some of the most compelling and well-replicated findings in psilocybin research concern end-of-life distress. Griffiths and Johnson's Johns Hopkins studies found that a single high-dose psilocybin session produced durable, large-magnitude reductions in death anxiety, depression, and meaninglessness in cancer patients, with effects persisting at six-month follow-up in the majority of participants (Griffiths et al., 2016). Comparable findings emerged from parallel trials at NYU. This is among the strongest and most consistent evidence in the field, and it is these results that first shifted mainstream scientific opinion.

Addiction

Preliminary findings suggest potential for addiction treatment, though evidence remains at earlier stages than for depression. Johnson and colleagues found substantial abstinence rates in a pilot study of smoking cessation (80% at six months), and a small trial at NYU found significant reductions in alcohol use disorder. Larger randomised trials are underway. Mechanistic accounts suggest psilocybin may facilitate interruption of rigid, compulsive cognitive patterns, consistent with its broader effects on psychological flexibility.

OCD and eating disorders

Early-phase research has explored psilocybin for obsessive-compulsive disorder, anorexia nervosa, and other conditions characterised by rigid, repetitive patterns of cognition and behaviour. Results are preliminary and sample sizes small, but the mechanistic rationale, loosening top-down cognitive constraints, has generated enough interest to fund larger controlled trials currently underway.

Nature-relatedness and ecological concern

Lyons and Carhart-Harris (2018) found increased nature-relatedness and decreased authoritarian political attitudes following psilocybin in a clinical sample. Kettner and colleagues (2019) found significant increases in nature-relatedness following psilocybin experiences that persisted at 2-week, 4-week, and 2-year follow-up, and were mediated by ego dissolution during the experience. These are correlational findings with significant methodological constraints (self-selected samples, self-report measurement, functional unblinding) but the consistency across research groups warrants serious attention. The relationship between psilocybin, ego-dissolution, and ecological re-orientation is one of the most intriguing patterns in the literature.

Caveats that matter

The research landscape is genuinely promising, but it is also characterised by small sample sizes, limited blinding, self-selected populations, short follow-up periods, and the challenge of separating drug effects from therapy effects and expectancy effects. The most important finding may be that psilocybin is not a magic bullet: outcomes depend substantially on dose, setting, psychological support, and integration. Functional unblinding (participants knowing they received psilocybin) and demand characteristics (wanting to report improvement) are structural confounds that current trial design cannot fully eliminate. These limitations do not negate the findings, but they are reasons for careful, qualified interpretation rather than triumphalist claims.

Risks & Contraindications

Psilocybin's physiological toxicity is low. No confirmed human fatalities from psilocybin toxicity alone are documented in the clinical literature, and it does not produce respiratory depression, the mechanism by which opioids are lethal. The most significant risks are psychological and contextual.

Psychological risks

Psychological overwhelm, sometimes called a "bad trip", is the most common adverse experience. This can range from transient anxiety to genuinely distressing and disorienting experiences that feel unmanageable. Adequate preparation, a safe environment, and the presence of a trusted person dramatically reduce but do not eliminate this risk. At very high doses, the loss of ordinary self-reference can be terrifying for people who are not expecting or prepared for it. Careful dose selection, especially for early experiences, is one of the most important harm-reduction decisions available.

Psychological difficulties following a psilocybin experience, sometimes called "integration challenges", are underreported and real. These can include temporary emotional destabilisation, existential difficulty, or the emergence of psychological material that was previously suppressed. This is not always unwelcome, but it requires attention and support.

Medical contraindications

A personal or family history of schizophrenia spectrum disorders or bipolar I disorder is the most significant medical contraindication. These conditions involve a vulnerability to psychosis that psychedelics can precipitate or exacerbate. This contraindication is taken seriously in all clinical research and should be taken seriously in any context. Other relevant considerations include a history of severe trauma, active psychosis, and certain cardiac conditions (psilocybin can mildly raise heart rate and blood pressure).

Drug interactions

Individuals taking SSRIs often report little or no effect at typical doses. Some people discontinue SSRIs to use psilocybin, which should only be done under medical supervision; SSRI discontinuation syndrome is real and can be serious, particularly with paroxetine and venlafaxine (an SNRI). Lithium combined with psychedelics has produced seizures in case reports and should be considered a firm contraindication. MAOIs can potentiate effects and duration unpredictably. Stimulants and cannabis can amplify intensity in ways that increase psychological risk.

Rare persistent effects

HPPD (hallucinogen persisting perception disorder), persistent visual disturbances following psychedelic use, is rare but documented. Its aetiology is poorly understood. Risk appears to be higher with frequent heavy use, use of multiple psychedelics, and use in people with underlying visual cortex sensitivity. It is not the same as a flashback in the colloquial sense.

Avoiding wild mushroom misidentification

This is a harm-reduction point of genuine seriousness. Several highly toxic fungal species (notably members of the Galerina genus, which contain amatoxins that cause fatal liver failure) can be confused with psilocybin-producing species by inexperienced foragers. Reagent testing (using Ehrlich reagent, which produces a purple reaction with indole-containing compounds including psilocybin) provides meaningful verification for dried mushrooms or extracts, but does not substitute for proper species identification. Unless you are confident in your mycological identification skills, cultivated mushrooms from trusted sources represent a substantially lower risk profile than foraged ones.

Testing & Harm Reduction

Reagent testing

The primary harm reduction tool for verifying that a substance contains psilocybin is the Ehrlich reagent, a chemical solution that turns purple/violet on contact with indole alkaloids, including psilocybin and psilocin. A positive Ehrlich reaction does not confirm the specific compound or its purity, but it does confirm the presence of an indole alkaloid, which is a meaningful safety check. Critically, Ehrlich does not react with many common adulterants (including fentanyl analogues, though fentanyl is rarely reported as a psilocybin adulterant). For comprehensive checking, the Hofmann reagent can be used alongside Ehrlich for confirmation.

Reagent test kits are legal in most jurisdictions and available from harm reduction suppliers such as DanceSafe and various online vendors. Testing requires only a small scraping from the material being checked, a few milligrams. A negative or unexpected colour reaction warrants discarding the material entirely.

Wild mushroom identification

If foraging for wild psilocybin mushrooms, accurate identification is essential, several toxic or deadly species can be superficially similar to common psilocybin species. Galerina marginata, which contains amatoxins causing potentially fatal liver damage, can resemble certain Psilocybe species. Always use multiple identification guides specific to your region, have specimens verified by an experienced mycologist before consuming, and use the blue staining reaction (bluing of flesh when cut or bruised, caused by oxidation of psilocin) as a supporting indicator, though not a definitive one. When in doubt, do not consume.

Core harm reduction principles

The psychedelic harm reduction community has developed a set of principles borne out by decades of experience in clinical, ceremonial, and informal settings. The most consistently protective factors are: knowing and honestly assessing your psychological history and current state before an experience; starting with a lower dose than you think you need, especially with unfamiliar material; having a trusted, sober companion present for higher-dose experiences; preparing your physical environment carefully so it feels safe and beautiful; having a clear intention without being rigidly attached to a specific outcome; and having an integration plan, some structure for reflection and support in the days following. See our Assessment and Preparation pages for detailed guidance on each of these.

Legal Status

Psilocybin is classified as a controlled substance in most jurisdictions worldwide. The following reflects the landscape as of early 2025; regulatory positions are actively shifting and should be verified with current sources before taking any action.

Canada: Psilocybin mushrooms are a Schedule III controlled substance under the Controlled Drugs and Substances Act. Simple possession is technically a criminal offence, though enforcement is inconsistent. Health Canada's Section 56 exemption process allows individual patients, researchers, and practitioners to apply for legal access on compassionate or research grounds, several hundred exemptions have been granted, primarily for palliative care and training contexts.

United States: Psilocybin is Schedule I under the Controlled Substances Act at the federal level, illegal to possess, sell, or cultivate. State and local laws vary: Oregon (Measure 109, 2020) created a regulated psilocybin services framework; Colorado (Proposition 122, 2022) is implementing a similar model. Multiple cities (Denver, Oakland, Santa Cruz, Seattle, and others) have deprioritised or effectively decriminalised possession of psilocybin mushrooms, though federal and state law remains unchanged.

Australia: Became the first country to permit prescribing of psilocybin by authorised psychiatrists, effective July 2023, for treatment-resistant depression and PTSD under specific clinical conditions.

Netherlands: Psilocybin mushrooms are illegal, but psilocybin-containing truffles (sclerotia of certain Psilocybe species) remain in a legal grey area and are sold openly in smart shops.

Jamaica, British Virgin Islands, and some other Caribbean jurisdictions: Psilocybin mushrooms are not scheduled, and legal retreat operations exist. These destinations have become destinations for international psychedelic retreats as a result.

In most other jurisdictions (including the UK, most of Europe, and the majority of Latin America, Asia, and Africa) psilocybin remains a controlled substance with varying penalties for possession. See our Law page for more detail.

If You Are Considering This

The general groundwork applies here as it does everywhere on this site, and it lives on assessment, preparation, and integration. Set an intention, arrange the space, have a sober person present, plan the music in advance, and give the days afterwards to reflection rather than obligations. None of that is specific to psilocybin, and the guides cover it properly.

Four things are specific to psilocybin.

A gram is not a gram

Potency varies more than people expect, and it varies along three axes at once. Different species differ substantially by dry weight, with P. azurescens and P. cyanescens several times stronger than the P. cubensis that all the standard dose figures assume. Different cultivars of cubensis differ from one another. And individual flushes from a single grow differ, with the alkaloid content unevenly distributed even within one mushroom. The dosage reference is a starting point for known cubensis, and it is not transferable to material you cannot identify.

Two practical consequences. Weigh dried rather than fresh, since fresh mushrooms are roughly ten times heavier for the same dose and the ratio is not fixed. And with any unfamiliar batch, take meaningfully less than your usual amount the first time and treat that session as calibration.

Identification matters more than testing

Unlike most substances here, the risk is not what someone cut it with. Foraged mushrooms carry a real misidentification risk, and several genuinely dangerous species resemble small brown psilocybin mushrooms closely enough to have killed people. Testing and harm reduction covers this. If you did not grow it or cannot identify it to species with confidence, that is the problem to solve first.

Clear the day, not the week

Effects run about four to six hours with a further hour or two of settling, which makes psilocybin considerably more manageable to plan around than LSD or mescaline. Take it in the morning or early afternoon and you will be yourself by evening and functional the next day. This is genuinely one of psilocybin's practical advantages, and there is no reason to give up a weekend for it.

Tolerance builds quickly

A repeat dose within a few days will do much less, and increasing the amount to compensate is a poor trade. Roughly two weeks restores baseline sensitivity. This matters mostly because it removes any reason to hurry: the next experience is more useful after the last one has been worked through, which is what integration is for.

Frequently Asked Questions